MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss applicable
to common...
-$6,396K
Fair value
adjustment of warrants
-$20,305K
Interest income
$793K
Loss from operations
-$26,182K
Interest expense
$1,312K
Total operating
expenses
$26,182K
Research and development
expense, total
$20,527K
General and
administrative expense, total
$5,655K
Back
Back
Income Statement
source: myfinsight.com
Syros Pharmaceuticals, Inc. (SYRS)
Syros Pharmaceuticals, Inc. (SYRS)